We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Home » FDA Adds Fourth Indian Site to Ranbaxy’s Consent Decree
FDA Adds Fourth Indian Site to Ranbaxy’s Consent Decree
October 7, 2013
In an enforcement action industry experts say signals FDA doubts about the generic giant’s culture of quality, the agency last month added Ranbaxy’s Mohali, India, facility to a consent decree it signed in January 2012 and issued an import alert on the plant, which makes oral solids.
To View This Article:
Login
Subscribe To Drug GMP Report
Drug GMP Report Subscription
A one-year subscription to Drug GMP Report (DGR) provides thorough analysis and interpretation of ever-changing U.S. and international good manufacturing practice (GMP) regulations, FDA enforcement trends, warning letters and more. Each monthly issue is packed with the latest on inspection hot spots, developments in certification procedures, electronic data requirements and evolving trends in drug GMP enforcement.
In each issue you get professionally researched, fully vetted, expertly written articles by our experienced staff for the kind of quick-read monthly update you need to stay current — without having to waste a minute of your busy work day on unproductive internet searches.
PLUS: in every issue, you get links to additional documents that support DGR’s articles, such as draft and final guidances, 483s and warning letters, proposed rules, closeout letters, full text of proposed legislation, and many others.
There’s absolutely no risk to you. You get our 100% Money-Back Guarantee: If at any time, for any reason, you become dissatisfied with Drug GMP Report, you may cancel your subscription and receive a full refund. No questions asked.
So, why wait? Become a subscriber to Drug GMP Report today. It couldn’t be easier.
